The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Aspirin Use and Risk of Colorectal Cancer According to BRAF Mutation Status
Open accessAbstract
IMPORTANCE: Aspirin use reduces the risk of colorectal carcinoma. Experimental evidence implicates a role of RAF kinases in up-regulation of prostaglandin-endoperoxide synthase 2 (PTGS2, cyclooxygenase 2), suggesting that BRAF-mutant colonic cells might be less sensitive to the antitumor effects of aspirin than BRAF-wild-type neoplastic cells. OBJECTIVE: To examine whether the association of aspirin intake with colorectal cancer risk differs according to status of tumor BRAF oncogene mutation. DESIGN AND SETTING: We collected biennial questionnaire data on aspirin use and followed up participants in the Nurses' Health Study (from 1980) and the Health Professionals Follow-up Study (from 1986) until July 1, 2006, for cancer incidence and until January 1, 2012, for cancer mortality. Duplication-method Cox proportional cause-specific hazards regression for competing risks data was used to compute hazard ratios (HRs) for colorectal carcinoma incidence according to BRAF mutation status. MAIN OUTCOMES AND MEASURES: Incidence of colorectal cancer cases according to tumor BRAF mutation status. RESULTS: Among 127,865 individuals, with 3,165,985 person-years of follow-up, we identified 1226 incident rectal and colon cancers with available molecular data. Compared with nonuse, regular aspirin use was associated with lower BRAF-wild-type cancer risk (multivariable HR, 0.73; 95% CI, 0.64 to 0.83; age-adjusted incidence rate difference [RD], -9.7; 95% CI, -12.6 to -6.7 per 100,000 person-years). This association was observed irrespective of status of tumor PTGS2 expression or PIK3CA or KRAS mutation. In contrast, regular aspirin use was not associated with a lower risk of BRAF-mutated cancer (multivariable HR, 1.03; 95% CI, 0.76 to 1.38; age-adjusted, incidence RD, 0.7; 95% CI, -0.3 to 1.7 per 100,000 person-years: P for heterogeneity = .037, between BRAF-wild-type vs BRAF-mutated cancer risks). Compared with no aspirin use, aspirin use of more than 14 tablets per week was associated with a lower risk of BRAF-wild-type cancer (multivariable HR, 0.43; 95% CI, 0.25 to 0.75; age-adjusted incidence RD, -19.8; 95% CI, -26.3 to -13.3 per 100,000 person-years). The relationship between the number of aspirin tablets per week and colorectal cancer risk differed significantly by BRAF mutation status (P for heterogeneity = .005). CONCLUSIONS AND RELEVANCE: Regular aspirin use was associated with lower risk of BRAF-wild-type colorectal cancer but not with BRAF-mutated cancer risk. These findings suggest that BRAF-mutant colon tumor cells may be less sensitive to the effect of aspirin. Given the modest absolute risk difference, further investigations are necessary to determine clinical implications of our findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rothwell, P. M., Wilson, M., Elwin, C.-E., Norrving, B., Algra, A., Warlow, C. P., & Meade, T. W. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61543-7 · Cited by 1,351
Flossmann, E., & Rothwell, P. M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60747-8 · Cited by 820
Prognostic Role of PIK3CA Mutation in Colorectal Cancer: Cohort Study and Literature Review
Liao, X., Morikawa, T., Lochhead, P., Imamura, Y., Kuchiba, A., Yamauchi, M., Nosho, K., Qian, Z. R., Nishihara, R., Meyerhardt, J. A., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2410 · Cited by 258
Self-citationIdentification of a Poor-Prognosis BRAF-Mutant–Like Population of Patients With Colon Cancer
Popovici, V., Budinska, E., Tejpar, S., Weinrich, S., Estrella, H., Hodgson, G., Van Cutsem, E., Xie, T., Bosman, F. T., Roth, A. D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.5814 · Cited by 236
Cited by
The updated landscape of tumor microenvironment and drug repurposing
Jin, M.-Z., & Jin, W.-L. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00280-x · Cited by 1,262
Harirforoosh, S., Asghar, W., & Jamali, F. (2014) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3vw2f · Cited by 960
Metabolic targets for cancer therapy
Galluzzi, L., Kepp, O., Heiden, M. G. V., & Kroemer, G. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4145 · Cited by 711
Aspirin and colorectal cancer: the promise of precision chemoprevention
Drew, D. A., Cao, Y., & Chan, A. T. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.4 · Cited by 453
Self-citationEpidemiology of colorectal cancer
Boyle, P., & Leon, M. E. (2002) · British Medical Bulletin · doi:10.1093/bmb/64.1.1 · Cited by 437
Metadata
- Authors
- Nishihara, R., Lochhead, P., Kuchiba, A., Jung, S., Yamauchi, M., Liao, X., Imamura, Y., Qian, Z. R., Morikawa, T., Wang, M., Spiegelman, D., Cho, E., Giovannucci, E., Fuchs, C. S., Chan, A. T., & Ogino, S.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2013-06-26
- Volume
- 309
- Issue
- 24
- Pages
- 2563
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1999571408
- Cited by
- 166
- References
- 4
- FWCI
- 18.89
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Aspirin Use and Risk of Colorectal Cancer According to BRAF Mutation Status. https://app.cochat.ai/papers/10.1001/jama.2013.6599
- The paper
- Nishihara, R., Lochhead, P., Kuchiba, A., Jung, S., Yamauchi, M., Liao, X., Imamura, Y., Qian, Z. R., Morikawa, T., Wang, M., Spiegelman, D., Cho, E., Giovannucci, E., Fuchs, C. S., Chan, A. T., & Ogino, S. (2013). Aspirin Use and Risk of Colorectal Cancer According to BRAF Mutation Status. JAMA. https://doi.org/10.1001/jama.2013.6599
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.